找化学品上960化工网!
960化工网

缬沙坦 | 137862-53-4

缬沙坦
Valsartan
137862-53-4
C24H29N5O3
435.5188
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:缬沙坦结构式
缬沙坦MSDS
125307697
缬沙坦价格
简介
       缬沙坦(Valsartan)白色结晶粉末,为一新型抗高血压药.是非肽血管紧张素ⅡAT1受体拮抗剂避免了钙拮抗剂和ACEI的不良反应.疗效显著,耐受性好,临床用于治疗高血压症。
名称和标识符
MDL MFCD00865840
InChIKey ACWBQPMHZXGDFX-QFIPXVFZSA-N
Inchi 1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
SMILES O([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C([H])([H])C1C([H])=C([H])C(C2=C([H])C([H])=C([H])C([H])=C2C2N=NN([H])N=2)=C([H])C=1[H])=O
别名信息
- 中文别名 -
  • 缬沙坦
  • N-(1-戊酰基)-N-[4-[2-(1H-四氮唑-5-基)苯基]苄基]-L-缬氨酸
  • 盐酸氨溴索杂质D
  • CGP一48933:DIOVAN
  • N-(1-氧戊基)-N-[[2'(-(1H-四唑-5-基)[1,1'(-联苯]-4-基]甲基]-L-缬氨酸
  • 颉沙坦
  • 缬沙坦 EP标准品
  • 缬沙坦 USP标准品
  • 缬沙坦标准品
  • 缬沙坦标准品(JP)
  • 缬沙坦峰鉴别 EP标准品
  • 缬沙坦系统适应性 EP标准品
  • 缬沙坦杂质
  • 辛伐司他汀
  • N-戊酰基-N-[2'-(1H-四唑-5-基)联苯-4-基甲基]-L-缬氨酸
  • 缬沙坦(对照品)
- 英文别名 -
  • Valsartan
  • CGP-48933
  • VALSARTAN, MM STANDARD
  • VALSARTAN, USP STANDARD
  • VALSARTAN, RELATED COMPOUND A(R)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE USP STANDARD
  • VALSARTAN, RELATED COMPOUND C(S)-N-VALERYL-N-([2'-(1-H-TETRAZOLE)-5-YL)-BIPHENYL-4-YL]-METHYL)-VALINE BENZYL ESTER USP STANDARD
  • N-[[(2-Cyano(1.1-Biphenyl)-4-Yl)Methyl]MethylEster]-L-Valine.Hydrochloride
  • ValsartanC24H29N503
  • Diovan, N-(1-Oxopentyl)-N-[[2(1H-tetrazol-5-yl)[1,1biphenyl]-4-yl]methyl]-L-valine, CGP-48933
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
  • Nisis
  • Tareg
  • (S)-2-(N-((2''-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID
  • N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • CGP 48933
  • GMP
  • L-Valsartan
  • N-(1-N.PENTANOYL)-N-[[2''-(1H-TETRAZOL-5-YL)[1'',1- BIPHENYL]-4-YL]METHYL]-L-VALINE
  • N-(1-Oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
  • Valsartan API
  • Valsartane
  • Valsratan
  • N-(1-Oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine
  • 3-Methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoic acid
  • N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
  • Diovan
  • [ "" ]
  • Provas
  • Exforge
  • N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
  • 80M03YXJ7I
  • C24H29N5O3
  • (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
  • Kalpres
  • Valsarta
  • CHEBI:9927
  • SBI-0206738.P001
  • DS-1248
  • BV164506
  • L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI)
  • SMR000466318
  • N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
  • ENTRESTO COMPONENT VALSARTAN
  • N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine
  • HMS3651E04
  • (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • Spectrum2_001120
  • Prexxartan
  • AKOS015994698
  • VAL-489
  • DAFIRO COMPONENT VALSARTAN
  • NSC 758927
  • AB00639940-06
  • KBio2_007423
  • VALSARTAN [INN]
  • NSC-758927
  • EC 604-045-2
  • N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
  • VALSARTAN COMPONENT OF COPALIA
  • VALSARTAN [MART.]
  • HMS2232F05
  • HSDB 7519
  • VALSARTAN COMPONENT OF COPALIA-HCT
  • VALSARTAN (USP MONOGRAPH)
  • SPECTRUM1505209
  • KBio3_003006
  • AM90287
  • UNII-80M03YXJ7I
  • NC00278
  • (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
  • (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid
  • HMS1922L21
  • (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • KBioGR_001078
  • HMS2093K22
  • 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid
  • Valsartan, Pharmaceutical Secondary Standard
  • Certified Reference Material
  • VALSARTAN COMPONENT OF DAFIRO-HCT
  • VALSARTAN [WHO-DD]
  • MLS001424088
  • BYVALSON COMPONENT OF VALSARTAN
  • SW197658-2
  • (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid
  • VALSARTAN [USP MONOGRAPH]
  • valsartanum
  • VALSARTAN [USP-RS]
  • CHEMBL1069
  • (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • VALSARTAN COMPONENT OF IMPRIDA-HCT
  • HMS3715P12
  • 137863-60-6
  • Valzaar
  • valsartan (Diovan)
  • BDBM50049186
  • VALSARTAN [EMA EPAR]
  • V0112
  • VALSARTAN (EP IMPURITY)
  • SR-05000001928
  • EXFORGE COMPONENT VALSARTAN
  • DTXCID603735
  • N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine
  • EZR-104
  • VALTURNA COMPONENT VALSARTAN
  • Vals
  • (2~{S})-3-methyl-2-[pentanoyl-[[4-[2-(2~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
  • NSC758927
  • (S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid
  • (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • VALSARTAN [USAN]
  • (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid
  • VALSARTAN [HSDB]
  • Diovan (TN)
  • N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
  • KBio2_002287
  • (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine
  • VALSARTAN COMPONENT OF EXFORGE HCT
  • (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
  • CCG-101028
  • VALSARTAN (MART.)
  • VALSARTAN (USP-RS)
  • AB00639940-08
  • Valsartan, >=98% (HPLC)
  • BSPBio_003501
  • N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine
  • L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
  • N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
  • Spectrum4_000749
  • MLS000759423
  • VALSARTAN COMPONENT OF VALTURNA
  • MFCD00865840
  • (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • HB3381
  • (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine
  • (2S)-3-Methyl-2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)butanoic acid
  • HY-18204
  • KS-1194
  • N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine
  • (S)-2-(N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • s1894
  • VALSARTAN [VANDF]
  • Valpression
  • KBioSS_002289
  • BIDD:GT0345
  • N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine
  • Spectrum_001796
  • D00400
  • COPALIA COMPONENT VALSARTAN
  • DB00177
  • CCG-221275
  • VALSARTAN [EP IMPURITY]
  • C09CA03
  • NCGC00178027-11
  • (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
  • (2R)-3-Methyl-2-[pentanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]butanoic Acid (Valsartan (R)-Enantiomer)
  • VALSARTAN COMPONENT OF DIOVAN HCT
  • BRD-K45158365-001-05-6
  • Varexan
  • VALSARTAN (EP MONOGRAPH)
  • Valsartan, United States Pharmacopeia (USP) Reference Standard
  • CS-1967
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • COPALIA-HCT COMPONENT VALSARTAN
  • BRD-K45158365-001-02-3
  • VALSARTAN COMPONENT OF ENTRESTO
  • U35
  • Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard
  • GTPL3937
  • VALSARTAN [ORANGE BOOK]
  • EN300-6482022
  • EXFORGE HCT COMPONENT VALSARTAN
  • (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid
  • VALSARTAN COMPONENT OF EXFORGE
  • Valsartan- Bio-X
  • AC-4543
  • L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-(9ci)
  • (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
  • DAFIRO-HCT COMPONENT VALSARTAN
  • IMPRIDA-HCT COMPONENT VALSARTAN
  • (S)-N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-methyl)-valine
  • valsartan
  • VALSARTAN COMPONENT OF IMMPRIDA
  • AB00639940_11
  • Valsartan (JP17/USP/INN)
  • (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
  • [3H]valsartan
  • J-007068
  • BCP05184
  • AKOS015914315
  • Valsartan (USAN:USP:INN:BAN)
  • Z1379303659
  • GTPL593
  • Spectrum3_001831
  • Miten
  • Kalpress
  • N-pentanoyl-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-L-valine
  • Spectrum5_001582
  • SPBio_001260
  • Q155472
  • IMPRIDA COMPONENT VALSARTAN
  • KBio2_004855
  • (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoicacid
  • AGSAV301 COMPONENT VALSARTAN
  • L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
  • DTXSID6023735
  • 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
  • Valsartana
  • Pharmakon1600-01505209
  • ACWBQPMHZXGDFX-QFIPXVFZSA-N
  • 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid
  • DIOVAN HCT COMPONENT VALSARTAN
  • VALSARTAN [EP MONOGRAPH]
  • Valsartan,(S)
  • HMS2051L12
  • NCGC00178027-08
  • Valtan
  • SR-05000001928-1
  • Valsartan, European Pharmacopoeia (EP) Reference Standard
  • 137862-53-4
  • VALSARTAN [JAN]
  • Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard
  • N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE
  • SCHEMBL2542
  • N-(1-Oxopentyl)-N-
  • VALSARTAN [MI]
  • VALSARTAN COMPONENT OF BYVALSON
  • AB00639940_09
  • (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-
  • (2S)-3-methyl-2-(N-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid
  • Valsartan [USAN:USP:INN:BAN]
物化性质
实验特性
LogP 4.16170
PSA 112.07000
Merck 9916
折射率 1.586
沸点 684.9 °C at 760 mmHg
熔点 117°C(lit.)
闪点 368ºC
溶解度 DMSO: ≥20mg/mL
颜色与性状 白色结晶粉末
稳定性 Hygroscopic
溶解性 DMSO: ≥20mg/mL
敏感性 对湿度敏感
比旋光度 -55.0° - -70.0° (c=1, MeOH)
光学活性 [α]/D -55 to -70°, c = 1 in methanol
密度 1.212g/cm3
计算特性
精确分子量 435.22700
氢键供体数量 2
氢键受体数量 6
可旋转化学键数量 10
同位素质量 435.22704
重原子数量 32
复杂度 608
同位素原子数量 0
确定原子立构中心数量 1
不确定原子立构中心数量 0
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP) 4.4
互变异构体数量 2
表面电荷 0
拓扑分子极性表面积 112
国际标准相关数据
EINECS 604-045-2
海关数据
海关数据

中国海关编码:

2933990090

概述:

2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

申报要素:

品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期

Summary:

2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

生产方法和用途
用途

本品为一新型抗高血压药.是非肽血管紧张素ⅡAT1受体拮抗剂避免了钙拮抗剂和ACEI的不良反应.疗效显著,耐受性好,临床用于治疗高血压症。

生产方法

2'-氰基联苯-4-醛(I)和L-缬氨酸甲酯进行还原胺化,得到的化合物(Ⅱ)再用戊酰氯进行酰化,层析后得到化合物(II)。然后和Bu3SnN3进行反应,引入四唑,再水解即得产物。

相关文献
专业数据库参考
PubChemId 125307697
参考资料
Reaxys RN 7754038
Beilstein MFCD00865840
缬沙坦推荐生产厂家
960化工网为您提供缬沙坦专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:137862-53-4,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等
平台客服 平台客服

平台在线客服